BCAL Diagnostics Ltd

All roads will lead to Singapore in early October with the important Spark Plus Aussie Equities Day investment show being staged in the lead-up to the local grand prix motoring event. The 2025 Spark Plus Aussie Equities Day is the 4th installment of their flagship event which aims to introduce a range of Australian companies to […]

BCAL Diagnostics (ASX: BDX) has launched a first-in-class blood test known as BREASTEST plus to address the challenge of high breast density, which can impact standard-of-care breast cancer screening practices. The company designed the lipid test for use alongside traditional mammogram imaging and it has been validated to meet the challenge of high breast density, […]

While international influences such as the surprise jump in US bond yields had a big impact on the Australian share market overall, local factors also played a big part in some significant price volatility in many individual shares. By the close of trade on Friday the ASX 200 managed to reverse an earlier fall to […]

Australian biotechnology company BCAL Diagnostics (ASX: BDX) has announced breakthrough results from a clinical study of its non-invasive blood-based test for detecting early-stage breast cancer. Sponsored by US commercialisation partner Precion Inc, the study achieved a test sensitivity rating of 90% and a specificity of 85.5%, both of which were consistent with the findings of […]